Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Evkeeza Market Revenue Growth Supported By A CAGR Of % Through 2030
The historical growth was driven by the limited efficacy of conventional statins, the longstanding impact of familial hypercholesterolemia, the early introduction of biologic lipid therapies, unmet medical requirements among HoFH patients, and the uptake of treatments guided by specialists.
The expansion observed during the forecast period is driven by a higher prevalence of genetic screening for lipid disorders, a growing uptake of biologic therapies, broader reimbursement coverage for rare diseases, progress in lipid metabolism studies, and an increase in specialized cardiology facilities. Key developments shaping this period encompass the broadening application of monoclonal antibody treatments, heightened attention to uncommon lipid conditions, the emergence of precision-based lipid-lowering approaches, greater utilization of targeted ANGPTL3 inhibitors, and enhanced results in managing severe hypercholesterolemia.
Download A Free Sample Report For Comprehensive Market Insights:
Evkeeza Market Opportunity Drivers: What Is Creating New Revenue Potential?
The expected growth of the evkeeza market in the years ahead is significantly influenced by the rising incidence of genetic disorders. These disorders, which stem from DNA abnormalities like gene mutations or chromosomal changes, are becoming more common due to enhanced diagnostic methods and increased environmental triggers. A key application of evkeeza is in managing homozygous familial hypercholesterolemia (HoFH), a genetic condition, where it works by blocking ANGPTL3 to reduce LDL cholesterol. Supporting this trend, the American Society of Hematology reported in June 2024 that by 2050, the worldwide number of people with sickle cell disease (SCD) could rise by about 30 percent. Consequently, the growing prevalence of genetic ailments is fueling the expansion of the evkeeza market.
An upsurge in drug approvals is set to propel the evkeeza market forward in the coming period. Drug approvals represent the official process where regulatory bodies assess and permit pharmaceuticals for public use. This increase stems from biotechnology innovations that speed up drug discovery along with streamlined regulatory pathways, such as accelerated approval programs for urgent treatments. For evkeeza, these approvals boost its reach in treating homozygous familial hypercholesterolemia, enhance patient availability, and take advantage of benefits like orphan drug exclusivity. A case in point is from February 2024, when the Personalized Medicine Coalition noted that the US FDA approved 16 new personalized therapies for rare diseases in 2023, a sharp rise from just six in 2022. Thus, the growing number of drug approvals is driving the evkeeza market’s progress.
Evkeeza Market Segmentation And Category Breakdown
The evkeeza market covered in this report is segmented –
1) By Indication: Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
2) By Route Of Administration: Intravenous (IV) Infusion, Self-Administration, Subcutaneous (SC) Administration, Hospital Infusion Centers, Infusion In Ambulatory Care Settings
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
Evkeeza Market Innovation Trends Driving Future Development
A central driver in the evkeeza market involves securing regulatory clearances for medications, thereby broadening their availability and strengthening their role in managing homozygous familial hypercholesterolemia (HoFH) patients. Such clearances are official permissions issued by government or oversight bodies, enabling a drug, medical tool, or therapy to be commercialized and utilized by the public. As an example, in March 2023, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the United States, secured FDA approval for Evkeeza (evinacumab-dgnb) targeting children aged 5 to 11 years who have HoFH, a rare inherited condition marked by dangerously high LDL cholesterol levels. This approval represents the first time an ANGPTL3 inhibitor has been authorized for this pediatric group, offering a fresh therapeutic avenue for roughly 1,300 impacted individuals across the U.S. Evidence from clinical studies indicated that children receiving evkeeza in combination with other cholesterol-lowering treatments achieved an average 48% decrease in LDL-C levels over a 24-week period.
Evkeeza Market Competitive Analysis Of Major Industry Participants
Major companies operating in the evkeeza market are Regeneron Pharmaceuticals Inc.
Access The Complete Evkeeza Market Report:
Evkeeza Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the evkeeza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evkeeza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model